| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
| MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T | Frank Vinluan | 08/03/20 | Europe |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test | Frank Vinluan | 07/28/20 | New York |
| AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer | Frank Vinluan | 07/27/20 | Europe |
| Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More | Sarah de Crescenzo | 07/24/20 | National |
| Jazz Pharma Gets FDA Nod for New Drug to Treat Narcolepsy Symptoms | Sarah de Crescenzo | 07/22/20 | Europe |
| Vesigen Nabs $28M to Wrap “ARMMS” Around Large Molecule Drug Delivery | Frank Vinluan | 07/22/20 | Boston |
| Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves | Frank Vinluan | 07/21/20 | Europe |
| Roche, Jnana Enter Drug R&D Alliance Targeting Metabolism’s Gatekeepers | Frank Vinluan | 07/21/20 | Boston |
| GSK Pays CureVac $328M in mRNA Vaccines Pact—Excluding COVID-19 | Frank Vinluan | 07/20/20 | Europe |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Mallinckrodt’s Kidney Failure Drug Narrowly Wins Backing of FDA Panel | Frank Vinluan | 07/16/20 | Europe |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership | Sarah de Crescenzo | 07/09/20 | Boston |
| BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity | Frank Vinluan | 07/01/20 | Europe |
| With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash | Sarah de Crescenzo | 06/26/20 | National |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug | Sarah de Crescenzo | 06/15/20 | National |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
